In patients with confirmed relapsing or progressive MS, baseline serum NfL can predict short-term outcomes including clinical and cognitive performance (Disanto et al., 2017; Jakimovski et al., 2019b; Filippi et al., 2020). The gene discussed is NEFL; the disease is myeloid sarcoma.